NCT00697242 - Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults | Biotech Hunter

Enrollment

362

Participants

Timeline

Start Date

January 31, 1994

Primary Completion Date

November 30, 1995

Study Completion Date

November 30, 1995

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix™-B

Intramuscular injection, 3 doses

BIOLOGICAL

Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL

Intramuscular injection, 3 doses

Trial Locations (4)

GSK Clinical Trials Call Center, Vienna

GSK Clinical Trials Call Center, Ghent

GSK Clinical Trials Call Center, Hvidovre

GSK Clinical Trials Call Center, Reykjavik